SG174071A1 - Genes and polypeptides relating to breast cancers - Google Patents

Genes and polypeptides relating to breast cancers Download PDF

Info

Publication number
SG174071A1
SG174071A1 SG2011057932A SG2011057932A SG174071A1 SG 174071 A1 SG174071 A1 SG 174071A1 SG 2011057932 A SG2011057932 A SG 2011057932A SG 2011057932 A SG2011057932 A SG 2011057932A SG 174071 A1 SG174071 A1 SG 174071A1
Authority
SG
Singapore
Prior art keywords
polypeptide
seq
acid sequence
amino acid
polynucleotide
Prior art date
Application number
SG2011057932A
Other languages
English (en)
Inventor
Yusuke Nakamura
Toyomasa Katagiri
Shuichi Nakatsuru
Original Assignee
Oncotherapy Science Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncotherapy Science Inc filed Critical Oncotherapy Science Inc
Publication of SG174071A1 publication Critical patent/SG174071A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • C12Q1/485—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5035—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on sub-cellular localization
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57415—Specifically defined cancers of breast
    • G01N33/575—
    • G01N33/57515—
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G01N2333/91205—Phosphotransferases in general
    • G01N2333/9121—Phosphotransferases in general with an alcohol group as acceptor (2.7.1), e.g. general tyrosine, serine or threonine kinases
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2510/00—Detection of programmed cell death, i.e. apoptosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
SG2011057932A 2006-08-10 2007-08-10 Genes and polypeptides relating to breast cancers SG174071A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US83742806P 2006-08-10 2006-08-10
US84025006P 2006-08-25 2006-08-25
US91502207P 2007-04-30 2007-04-30

Publications (1)

Publication Number Publication Date
SG174071A1 true SG174071A1 (en) 2011-09-29

Family

ID=38627000

Family Applications (1)

Application Number Title Priority Date Filing Date
SG2011057932A SG174071A1 (en) 2006-08-10 2007-08-10 Genes and polypeptides relating to breast cancers

Country Status (8)

Country Link
US (2) US8673548B2 (cg-RX-API-DMAC7.html)
EP (1) EP2057187B1 (cg-RX-API-DMAC7.html)
JP (1) JP5339291B2 (cg-RX-API-DMAC7.html)
KR (1) KR20090064378A (cg-RX-API-DMAC7.html)
BR (1) BRPI0716498A2 (cg-RX-API-DMAC7.html)
CA (1) CA2660438A1 (cg-RX-API-DMAC7.html)
SG (1) SG174071A1 (cg-RX-API-DMAC7.html)
WO (1) WO2008018642A2 (cg-RX-API-DMAC7.html)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200512298A (en) 2003-09-24 2005-04-01 Oncotherapy Science Inc Method of diagnosing breast cancer
UA97787C2 (ru) 2005-07-29 2012-03-26 Таргитед Гроут, Инк. Защита доминантным негативным мутантным krp-белком ингибирования активного циклин-cdk-комплекса krp-белком дикого типа
JP5514453B2 (ja) * 2008-03-04 2014-06-04 株式会社キノファーマ 発光タンパク質を用いたリン酸化酵素阻害物質のスクリーニング方法
EP2275567A1 (en) * 2009-07-15 2011-01-19 Rheinische Friedrich-Wilhelms-Universität Bonn Nucleic acid expression construct and its use as a cell proliferation marker
AU2011223883B2 (en) * 2010-03-01 2015-10-08 Cavion, Inc. Cancer diagnosis and imaging
EP2638167A4 (en) * 2010-11-12 2014-03-26 Targeted Growth Inc DOMINANT NEGATIVE MUTANT KIP PROTEINS IN ZEA-MAIZE AND METHOD FOR THEIR USE
EP2697378A4 (en) 2011-04-11 2014-10-01 Targeted Growth Inc IDENTIFICATION AND USE OF KRP MUTANTS IN PLANTS
WO2012142116A2 (en) 2011-04-11 2012-10-18 Targeted Growth, Inc. Identification and use of krp mutants in wheat
US9725490B2 (en) 2011-07-29 2017-08-08 Tokushima University ERAP1-derived peptide and use thereof
ES2665576T3 (es) * 2011-10-28 2018-04-26 Oncotherapy Science, Inc. Péptidos TOPK y vacunas que los incluyen
CA3106312C (en) * 2011-12-16 2025-09-23 National University Corporation Tokyo Medical And Dental University CHIMERIC DOUBLE-STRANDED NUCLEIC ACID
GB201121924D0 (en) * 2011-12-20 2012-02-01 Fahy Gurteen Labs Ltd Detection of breast cancer
WO2016011143A1 (en) * 2014-07-15 2016-01-21 Temple University Of The Commonwealth System Of Higher Education Stabilized peptide fragments from redoxin proteins as cancer biomarkers
CN104497147B (zh) * 2014-12-23 2018-07-03 四川大学 一种双受体识别的串联型穿膜肽修饰的肿瘤靶向纳米递药系统
JP6923135B2 (ja) 2016-01-19 2021-08-18 国立大学法人徳島大学 がん治療用ペプチド及びそれを含む医薬組成物
US20210206818A1 (en) 2016-01-22 2021-07-08 Modernatx, Inc. Messenger ribonucleic acids for the production of intracellular binding polypeptides and methods of use thereof
EP3656783A4 (en) 2017-07-19 2021-04-07 Tokushima University PEPTIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION WITH IT
CN114773480A (zh) * 2022-06-07 2022-07-22 厦门大学附属翔安医院 一种抗topk第32位丝氨酸残基磷酸化的抗体
CN116082447A (zh) * 2022-09-09 2023-05-09 湖南大学 一种多肽及其制备方法
CN117757789A (zh) * 2022-09-26 2024-03-26 领星生物科技（上海）有限公司 用于抑制肿瘤生长的siRNA及其应用

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6656698B1 (en) * 1999-06-30 2003-12-02 Millennium Pharmaceuticals, Inc. 12832, a novel human kinase-like molecule and uses thereof
EP1074617A3 (en) * 1999-07-29 2004-04-21 Research Association for Biotechnology Primers for synthesising full-length cDNA and their use
US6436703B1 (en) 2000-03-31 2002-08-20 Hyseq, Inc. Nucleic acids and polypeptides
AU2001296448A1 (en) 2000-10-03 2002-04-15 Curagen Corporation Tumor marker and methods of use
AU2002220265A1 (en) * 2000-11-03 2002-05-15 University Of Vermont And State Agricultural College Compositions for inhibiting grb7
CA2429343A1 (en) * 2000-11-17 2002-08-01 Hyseq, Inc. Nucleic acids and polypeptides
WO2002059271A2 (en) 2001-01-25 2002-08-01 Gene Logic, Inc. Gene expression profiles in breast tissue
US20030099974A1 (en) 2001-07-18 2003-05-29 Millennium Pharmaceuticals, Inc. Novel genes, compositions, kits and methods for identification, assessment, prevention, and therapy of breast cancer
AU2002357726A1 (en) 2001-11-15 2003-06-10 The Regents Of The University Of California Compositions and methods for the suppression of mammary epithelial cell proliferation
US6833247B2 (en) 2002-05-14 2004-12-21 Origene Technologies, Inc. Regulated prostate cancer genes
WO2003064599A2 (en) 2002-01-25 2003-08-07 Origene Technologies, Inc Cancer genes
US20030235533A1 (en) 2002-02-19 2003-12-25 Idec Pharmaceuticals Corporation Prostate specific genes and the use thereof in design or therapeutics
AU2003259913A1 (en) * 2002-08-19 2004-03-03 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
US20060194199A1 (en) 2002-09-30 2006-08-31 Oncotherapy Science, Inc. Method for diagnosing testicular seminomas
US6971476B2 (en) * 2003-09-05 2005-12-06 D B Industries, Inc. Safety harness
TW200512298A (en) 2003-09-24 2005-04-01 Oncotherapy Science Inc Method of diagnosing breast cancer
WO2006085684A2 (en) 2005-02-10 2006-08-17 Oncotherapy Science, Inc. Method of diagnosing bladder cancer
WO2006110593A2 (en) 2005-04-07 2006-10-19 Macrogenics, Inc. Biological targets for the diagnosis, treatment and prevention of cancer
EP1907582B1 (en) 2005-07-27 2012-01-04 Oncotherapy Science, Inc. Ect2 as a therapeutic target for esophageal cancer
EP1907580A2 (en) 2005-07-28 2008-04-09 Oncotherapy Science, Inc. Method for diagnosing and treating renal cell carcinoma
RS53552B1 (sr) 2007-10-11 2015-02-27 Astrazeneca Ab Derivati pirolo[2,3-d]pirimidina kao inhibitori protein kinaze b
KR20110079847A (ko) 2008-10-30 2011-07-08 온코세라피 사이언스 가부시키가이샤 7-하이드록시-벤조이미다졸-4-일-메타논 유도체 및 이를 함유하는 ｐｂｋ 저해제

Also Published As

Publication number Publication date
US8673548B2 (en) 2014-03-18
WO2008018642A3 (en) 2008-04-03
JP5339291B2 (ja) 2013-11-13
JP2010500003A (ja) 2010-01-07
WO2008018642A2 (en) 2008-02-14
US20140228238A1 (en) 2014-08-14
CA2660438A1 (en) 2008-02-14
EP2444417A1 (en) 2012-04-25
EP2057187A2 (en) 2009-05-13
KR20090064378A (ko) 2009-06-18
BRPI0716498A2 (pt) 2015-01-27
EP2057187B1 (en) 2016-12-28
US20110135647A1 (en) 2011-06-09
US9187557B2 (en) 2015-11-17

Similar Documents

Publication Publication Date Title
US9187557B2 (en) Genes and polypeptides relating to breast cancers
JP4921522B2 (ja) 非小細胞肺癌の診断のための方法
CN101835894A (zh) Ebi3、dlx5、nptx1和cdkn3用作肺癌治疗和诊断的靶基因
US20110263012A1 (en) Screening and therapeutic method for nsclc targeting cdca1-kntc2 complex
Fukukawa et al. Critical roles of LGN/GPSM2 phosphorylation by PBK/TOPK in cell division of breast cancer cells
JP2010512730A (ja) 肺癌の腫瘍マーカーおよび治療標的としてのｔｔｋ
WO2008023841A1 (en) Breast cancer-associated gene, melk, and its interactions with bcl-g
CN101068935B (zh) 与乳腺癌相关的基因和多肽
CN101528768A (zh) 与乳腺癌相关的基因和多肽
US20120214174A1 (en) Gene and polypeptide relating to breast cancer
US20120010266A1 (en) Tbc1d7 as tumor marker and therapeutic target for cancer
EP2444417B1 (en) Genes and polypeptides relating to breast cancers
CN101278060B (zh) 作为乳腺癌标志的基因galnt6和针对基因galnt6的小干扰rna
JP2012501166A (ja) 乳癌関連遺伝子ｒｑｃｄ１
JP2012506236A (ja) 抗肺がん化合物または抗食道がん化合物のスクリーニング方法